Breast Cancer
A phase IIIb study to characterize the efficacy and safety of ADJUVANT ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2- early breast cancer (ADJUVANT WIDER) (CLEE011O12001)
- Details
ClinicalTrials.gov ID:
NCT05827081
Diagnosis Type:
NA
USOR Number:
- Address
,
P: